Sanofi’s new R&D operations hub confirms China as the third pillar of Sanofi Global Clinical Sciences and Operations, joining facilities in France and the United States. With an investment of €66 million ($78 million), the Hub will support the clinical research and development of Sanofi’s innovative drugs by focusing on the management of global multi-center clinical trials data and files.…
FDA To Review Sanofi’s Zynquista As Potential Diabetes Treatment
The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. “If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by…
FDA Approves High Capacity, Long-Acting Insulin Pen
EMA to Review Sotagliflozin as Potential Treatment for Type 1 Diabetes
Sanofi, Regeneron to Make Praluent More Affordable for Patients with the Greatest Health Risk and Unmet Need
Sanofi And Regeneron To Increase Praluent Accessibility For High-Risk Patients
To help ensure more affordable and timely access to patients most in need, Sanofi and Regeneron Pharmaceuticals will offer U.S. payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent (alirocumab) Injection in alignment with a new value assessment for high-risk patients from the U.S. Institute for Clinical and Economic…
Evotec And Sanofi Plan To Create Infectious Disease R&D Platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France. In support of this platform, Sanofi will license most of its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit to Evotec. The…
FDA to Review Dupixent (Dupilumab) as Potential Treatment for Moderate-to-severe Asthma
Sanofi Reports 2 Percent Sales Drop In 4Q On U.S. Diabetes Drug Downturn
Sanofi delivers 2017 business EPS(1) in line with guidance. “In 2017, we continued to execute on our strategic goals with the strong launch of Dupixent, the positive pivotal data for cemiplimab and for dupilumab in asthma,” Olivier Brandicourt, Sanofi chief executive officer, commented. “At the same time, we managed the challenges in U.S. diabetes as well as the…
Sanofi, DNDi Seek European Medicines Agency Review for Sleeping Sickness Treatment
Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being developed in collaboration with the Drugs for Neglected Disease initiative (DNDi). It would be the first all-oral treatment under investigation for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), commonly known as sleeping sickness. It is hoped that this treatment…
Sanofi to Acquire Ablynx for 3.9 Billion Euros
Sanofi To Acquire Ablynx For $4.8 Billion
Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 ($55.64)…
Sanofi to Acquire Bioverativ for $11.6 Billion
Sanofi, Alnylam Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Sanofi, Principia Agree to Develop MS Drug Candidate
Sanofi, Principia Agree To Develop Multiple Sclerosis Drug Candidate
Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain…